Find Funding Opportunities

This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

The purpose of this NIH HEAL Initiative PAINCare Clinician Training Program(PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH)is to support a cohort of new and well-trained, independent investigators. The program will provide independent NIH research support during the early-career phase to help awardeesestablish independent research programs in areas support by the NIH HEAL InitiativesClinicalResearch in Pain Management program.

The purpose of this NIH HEAL Initiative PAINCare Clinician Training Program: PCTP): Mentored Clinical Scientist Development Awards (K08) (Clinical Trials Not Allowed)is to support a cohort of new and well-trained, independent investigators. The program will provide independent NIH research support during the early-career phase to help awardeesestablish independent research programs in areas support by the NIH HEAL InitiativesClinicalResearch in Pain Management program.

The purpose of this NIH HEAL Initiative PAINCare Clinician Training Program (PCTP): Mentored Patient-Oriented Research Career Development award (K23) (Clinical Trial Required) is to support a cohort of new and well-trained, independent investigators. The program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas support by the NIH HEAL Initiatives Clinical Research in Pain Management program.

The purpose of this NIH HEAL Initiative PAIN Care Clinician Training Program: PCTP): Mentored Clinical Scientist Development Awards (K08) (Clinical Trials Required) is to support a cohort of new and well-trained, independent investigators. The program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas support by the NIH HEAL Initiatives Clinical Research in Pain Management program.

The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.

The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.

Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.

(Reissue of PAR-18-665) This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIH's SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.